If approved, doravirine/islatravir would be the first two-drug HIV treatment regimen without an integrase inhibitor, ...

U.S. withdrawal of $4 billion in AIDS funding risks over 4 million deaths and 6 million new HIV infections by 2029 ...

The $4 billion that the United States pledged for the global HIV response for 2025 disappeared virtually overnight in January ...

A Bladen County woman appeared in court Thursday for the first time since being charged in the shooting death of her husband.

The Minister’s address was particularly notable for the announcement of a planned rollout of lenacapavir, a biannual ...

Gilead has partnered with Global Fund to supply lenacapavir for the prevention of HIV as pre-exposure prophylaxis (PrEP).

Robin Washington, chief operating and financial officer at Salesforce, talks agentic AI and offers career advice.

Arcus Biosciences' cancer drug candidate, quemliclustat, earns FDA orphan drug status, ensuring incentives and exclusivity.

For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both. The research service ...

Pomerantz LLP is investigating claims on behalf of investors of Gilead Sciences, Inc. (“Gilead” or the “Company”) (NASDAQ: GILD). Such investors are ...

Through a strategic, non-profit agreement, Gilead will supply up to two million doses of the long-acting HIV prevention drug ...